Hypofractionation for Prostate Cancer in Africa: A Feasibility Study

Active, not recruitingOBSERVATIONAL
Enrollment

182

Participants

Timeline

Start Date

December 30, 2021

Primary Completion Date

March 1, 2026

Study Completion Date

March 1, 2029

Conditions
Prostate Cancer
Interventions
RADIATION

Hypofractionated radiotherapy for low- and intermediate-risk prostate cancer patients

Hypofractionated radiotherapy for low- and intermediate-risk prostate cancer will be treated with 20x3 Gray (Gy), 5 days/week

RADIATION

Hypofractionated radiotherapy for high-risk prostate cancer patients

Hypofractionated radiotherapy for high-risk prostate cancer will be treated with 20x3.1 Gy, 5 days/week

Trial Locations (3)

Unknown

NSIA-LUTH Cancer Center, Lagos

Inkosi Albert Luthuli Central Hospital, Durban

Ocean Road Cancer Institute, Dar es Salaam

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Inkosi Albert Luthuli Central Hospital

UNKNOWN

collaborator

Erasmus Medical Center

OTHER

collaborator

Dana-Farber Cancer Institute

OTHER

collaborator

Nigeria Sovereign Investment Authority-Lagos University Teaching Hospital Cancer Center (NLCC)

UNKNOWN

lead

Muhimbili University of Health and Allied Sciences

OTHER